Cipla USA Inc. Recalls Cinacalcet Hydrochloride Tablets Over CGMP Deviations and N-Nitroso Impurities
Cipla USA Inc. has initiated a voluntary Class II recall for 113,336 bottles of Cinacalcet Hydrochloride Tablets nationwide due to Current Good Manufacturing Practice (CGMP) deviations and N-Nitroso Cinacalcet exceeding acceptable daily intake limits. This event, stemming from manufacturing in India, signals critical supply chain vulnerabilities and heightened regulatory scrutiny on impurity control. Procurement and regulatory teams must assess immediate supply risks and reinforce robust quality assurance protocols to mitigate similar future disruptions.
FDA Identifies CGMP Deviations and N-Nitroso Impurities in Cipla's Cinacalcet
Cipla USA Inc. has initiated a voluntary Class II recall for its Cinacalcet Hydrochloride Tablets, 30 mg, distributed nationwide in the USA. This significant regulatory action, designated recall number D-0449-2026, stems from critical Current Good Manufacturing Practice (CGMP) deviations identified during the manufacturing process. The primary concern is the presence of N-Nitroso Cinacalcet, a known genotoxic impurity, at levels exceeding the acceptable daily intake (ADI) limit established by regulatory authorities. This finding directly impacts product quality and patient safety, necessitating the removal of affected batches from the market. For procurement directors and regulatory affairs heads, this event underscores the imperative of rigorous supplier qualification and continuous monitoring of manufacturing sites, particularly those producing active pharmaceutical ingredients (APIs) and finished drug products internationally. The detection of N-Nitroso impurities, a recurring challenge across the pharmaceutical industry, highlights the need for robust impurity profiling and control strategies within quality management systems. Companies sourcing Cinacalcet or similar molecules must immediately review their supplier's nitrosamine risk assessments and mitigation plans to ensure compliance and prevent similar disruptions to their own supply chains and product portfolios.
Operational Impact: Cinacalcet Supply Disruption and Affected Batches
The voluntary recall by Cipla USA Inc. directly impacts the supply of Cinacalcet Hydrochloride Tablets, 30 mg, a critical medication. A total of 113,336 bottles are affected by this Class II recall, distributed across the United States. The specific lots identified are 4PB0526, 4PB0527, and 4PB0528, all with an expiry date of September 2026, as well as lot 5PB0173, expiring in January 2027. This substantial quantity represents a notable disruption to the market for generic Cinacalcet, which is manufactured by Cipla Ltd. in MIDC, Patalganga, India, and distributed by Cipla USA, Inc. from Warren, NJ. Supply chain VPs and business development executives must immediately assess their current inventory and demand for Cinacalcet. The ongoing status of this recall, initiated on March 16, 2026, with classification on April 10, 2026, means that affected product is actively being removed from circulation. This could lead to temporary shortages or increased pricing pressures for alternative sources. Understanding the specific lot numbers and expiry dates is crucial for identifying at-risk stock within your distribution channels and for communicating effectively with downstream partners and healthcare providers. Proactive measures to secure alternative supply or manage existing stock are paramount to minimize patient impact and maintain market presence.
Regulatory Scrutiny and Future Outlook for Generic Drug Manufacturing
This Class II recall of Cinacalcet Hydrochloride Tablets by Cipla USA Inc. reinforces the FDA's heightened scrutiny on manufacturing quality, particularly concerning genotoxic impurities like N-Nitroso compounds. While this is a firm-initiated voluntary recall, the underlying CGMP deviations and impurity exceedances are serious regulatory concerns. The FDA's classification of this event as Class II indicates that the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote, but the issue is significant enough to warrant market removal. For regulatory affairs heads and procurement directors, this event signals a continued focus by the FDA on the integrity of pharmaceutical manufacturing processes, especially within the global generic drug supply chain. Recent parallel events, such as other Class II recalls for sterility assurance or metallic contamination, underscore a broader trend of increased regulatory enforcement. Companies must anticipate more stringent requirements for impurity control, particularly for products manufactured in international facilities. Proactive investment in advanced analytical testing, robust quality management systems, and comprehensive supplier audits will be critical to navigate this evolving regulatory landscape and safeguard against future compliance risks and supply disruptions. This incident serves as a clear reminder that regulatory compliance is not merely a checkbox but a continuous commitment to product quality and patient safety.